Last reviewed · How we verify
NCT05721729
Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions
Phase 2 trial testing Mizagliflozin in Postbariatric Hypoglycemia in 15 participants. Completed in 1 June 2025.
1 May 2024
Quick facts
| Lead sponsor | Vogenx, Inc. |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 23 June 2023 |
| Primary completion | 1 May 2024 |
| Estimated completion | 1 June 2025 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Mizagliflozin — full drug profile →
- Placebo
Conditions studied
- Postbariatric Hypoglycemia — all drugs for Postbariatric Hypoglycemia →
Sponsor
Vogenx, Inc.
Who can join
Adults 18 to 75, any sex, with Postbariatric Hypoglycemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a phase 2 crossover, randomized, placebo-controlled, single-blind, repeat dose study in PBH subjects to determine the effect of mizagliflozin on adverse events and postprandial glucose excursions.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
OR08-04 Efficacy and Safety of the SGLT1 Inhibitor Mizagliflozin in Patients with Post-Bariatric Hypoglycemia
· 2025 -
Managing post-bariatric hypoglycemia: a systematic review of pharmacological therapies.
Sridharan K, Sivaramakrishnan G. · · 2025 · PMID 41126373 · DOI 10.1186/s13098-025-01988-y
Verify or expand the search:
- PubMed search for NCT05721729
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Mizagliflozin
Trials testing the same drug.
- NCT05541939 — Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia Subjects · Phase 2 · completed
Other recruiting trials for Postbariatric Hypoglycemia
Currently open trials in the same condition.
- NCT07029412 — Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI) · Phase 2 · recruiting
- NCT06896682 — Cortisol and Obesity - A Vicious Cycle? Hypoglycemia After Bariatric Surgery - Association With Cortisol Metabolism? · recruiting
Other Vogenx, Inc. trials
Trials by the same sponsor.
- NCT05541939 — Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia Subjects · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05721729 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Vogenx, Inc.
- Last refreshed: 18 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05721729.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing